05-636-AF488
Anti-phospho Histone H2A.X (Ser139), clone JBW301, Alexa Fluor™ 488 Conjugate Antibody
clone JBW301, from mouse, ALEXA FLUOR™ 488
Synonym(s):
Histone H2AX, H2a/x, Histone H2A.X
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
conjugate
ALEXA FLUOR™ 488
antibody form
purified antibody
antibody product type
primary antibodies
clone
JBW301, monoclonal
species reactivity
human
species reactivity (predicted by homology)
vertebrates (based on 100% sequence homology)
technique(s)
immunocytochemistry: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer139)
Gene Information
human ... H2AX(3014)
General description
Histone H2A.X is a variant of histone H2A, and is similarly associated with genomic DNA. However, histone is structurally different from other members of the H2A family in possessing a C-terminal tail that contains the Ser139 residue that is phosphorylated in response to breaks in double-stranded DNA. The phosphorylation of H2A.X is a rapid process that is mediated by ATM/ATR proteins.
Application
This Anti-phospho Histone H2A.X (Ser139) antibody, clone JBW301, Alexa Fluor™ 488 Conjugate is validated for use in ICC for the detection of phospho Histone H2A.X (Ser139).
Quality
Evaluated by Immunocytochemistry in untreated (negative control) and Staurosporin treated HeLa cells.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected phospho-Histone H2A.X (Ser139) in Staurosporin treated HeLa cells, and not in untreated HeLa cells.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected phospho-Histone H2A.X (Ser139) in Staurosporin treated HeLa cells, and not in untreated HeLa cells.
Target description
17 kDa calculated
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
ALEXA FLUOR is a trademark of Life Technologies
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lara H El Touny et al.
Oncotarget, 12(21), 2114-2130 (2021-10-23)
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/-ve/MMRproficient patients benefit from TMZ treatment, indicating a need for
Lidia F Hernandez et al.
Cell death discovery, 7(1), 134-134 (2021-06-06)
Ovarian cancer is the most lethal gynecological cancer in the US. Standard treatment consists of surgery followed by chemotherapies relying on apoptotic tumor cell death. Most women with advanced stage disease will relapse, suggesting that this disease is characterized by
Jolien Van den Bossche et al.
Cancers, 11(12) (2019-12-05)
Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division, is highly expressed in non-small cell lung cancer (NSCLC) making it an interesting drug target. We examined the in vitro therapeutic effects of volasertib, a Plk1 inhibitor, in combination
Lazina Hossain et al.
International journal of molecular sciences, 25(14) (2024-07-27)
Secondary lymphedema is caused by damage to the lymphatic system from surgery, cancer treatment, infection, trauma, or obesity. This damage induces stresses such as oxidative stress and hypoxia in lymphatic tissue, impairing the lymphatic system. In response to damage, vascular
Chien-Hsing Chang et al.
Molecular cancer therapeutics, 15(8), 1910-1919 (2016-05-22)
Sacituzumab govitecan (IMMU-132), an SN-38-conjugated antibody-drug conjugate, is showing promising therapeutic results in a phase I/II trial of patients with advanced Trop-2-expressing, metastatic, solid cancers. As members of the ATP-binding cassette (ABC) transporters confer chemotherapy resistance by active drug efflux
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service